Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed TherapeuticsGDTC +12.50%27 PB Ratio is 2.31 as of Jul. 25, 2026, which is 29% below its 10-year median of 3.26. GuruFocus rates GDTC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,229 Biotechnology companies, CytoMed Therapeutics ranks better than 61.11% on this metric.
The historical rank and industry rank for CytoMed Therapeutics's PB Ratio or its related term are showing as below:
GDTC'
s PB Ratio Range Over the Past 10 Years
Min: 1.82 Med: 3.26 Max: 6
Current: 2.31
During the past 6 years, CytoMed Therapeutics's highest PB Ratio was 6.00. The lowest was 1.82. And the median was 3.26.
GDTC's PB Ratio is ranked better than 61.11% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs GDTC: 2.31
During the past 12 months, CytoMed Therapeutics's average Book Value Per Share Growth Rate was -25.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 120.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 73.70% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of CytoMed Therapeutics was 181.00% per year. The lowest was 48.90% per year. And the median was 120.50% per year.
Back to Basics: PB Ratio
CytoMed Therapeutics (NAS:GDTC) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CytoMed Therapeutics PB Ratio Related Terms
CytoMed Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for CytoMed Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CytoMed Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CytoMed Therapeutics (GDTC) has a PB Ratio of 2.31 as of Jul. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CytoMed Therapeutics and its competitors. This is 29% below median its historical median of 3.26. Over the past decade, CytoMed Therapeutics' PB Ratio has ranged from 1.82 to 6.00. According to the industry distribution chart, CytoMed Therapeutics ranks #478 out of 1229 companies in the Biotechnology industry, placing it in the top 38.9%.
Is CytoMed Therapeutics' PB Ratio too high?
CytoMed Therapeutics' current PB Ratio of 2.31 is 29% below median its 10-year median of 3.26. Over the past 10 years, this metric has ranged from a low of 1.82 to a high of 6.00. The Biotechnology industry median PB Ratio is 2.79. CytoMed Therapeutics' value of 2.31 is 17.2% below this industry median. Based on the distribution chart, CytoMed Therapeutics ranks #478 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CytoMed Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' PB Ratio compare to LEXX and INAB?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #478 out of 1229 companies for PB Ratio. This puts CytoMed Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.79. CytoMed Therapeutics' value of 2.31 is 17.2% below this benchmark. Historically, CytoMed Therapeutics' own PB Ratio has ranged from 1.82 to 6.00 over the past decade. While the company's 10-year median is 3.26 vs. the industry median of 2.79, CytoMed Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoMed Therapeutics's current PB Ratio of 2.31 is 17.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CytoMed Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoMed Therapeutics's current PB Ratio is 2.31, which is 29% below median its own 10-year median of 3.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (GDTC) has a current PB Ratio of 2.31. The current PB Ratio is 2.31, which is 29% below median its 10-year median of 3.26 and 17.2% below the Biotechnology industry median of 2.79. CytoMed Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CytoMed Therapeutics (GDTC), the current PB Ratio is 2.31 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
27GF Score
Get the complete analysis for GDTC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDTC has been successfully added to your 
